Amgen

Investor's Business Daily

Amgen (AMGN) said its cholesterol drug, evolocumab, met the end goal of a 3rd late-stage trial. The drug belongs to a new class of PCSK9 inhibitors that could have sales of billions of dollars each year. Shares fell 0.6% to 123.60.

View Comments (0)